Images List Premium Download Classic

Breast Cancer

Breast Cancer-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Methods of detecting breast cancer brain metastasis with genomic and epigenomic biomarkers
The Translational Genomics Research Institute
October 12, 2017 - N°20170292163

The present invention provides a method of diagnosing a breast cancer central nervous system (cns) metastasis in a subject, comprising determining the expression level of at least one biomarker in a subject-derived brain or breast tissue comparing the subject-derived expression level with a normal control level obtained from normal brain or breast cells; and correlating an increase or decrease of ...
Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers
Merrimack Pharmaceuticals, Inc.
October 12, 2017 - N°20170291957

Provided are methods of suppressing growth of triple negative breast tumors and basal-like breast tumors by contacting tumor cells with an erbb3 inhibitor, e. G., an anti-erbb3 antibody. Also provided are methods for treating triple negative breast cancer or basal-like breast cancer in a patient by administering to the patient an erbb3 inhibitor, e. G., an anti-erbb3 antibody. The treatment ...
Reducing tumor burden by administering ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors
Chemocentryx, Inc.
October 12, 2017 - N°20170290808

The present invention provides methods for reducing tumor burden, tumor growth, tumor progression, and/or metastasis in a subject suffering from a solid tumor cancer such as triple negative breast cancer. The methods include administering to a subject in need thereof a therapeutically effective amount of a pd-l1 inhibitor or a pd-1 inhibitor in combination with a small molecule chemokine ...
Breast Cancer Patent Pack
Download 198+ patent application PDFs
Breast Cancer Patent Applications
Download 198+ Breast Cancer-related PDFs
For professional research & prior art discovery
inventor
  • 198+ full patent PDF documents of Breast Cancer-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Methods for diagnosis, prognosis and monitoring of breast cancer and reagents therefor
Garvan Institute Of Medical Research
October 05, 2017 - N°20170283886

The present disclosure provides methods and reagents for the diagnosis, prognosis or the monitoring of breast cancer, including various subtypes of breast cancer including, for example, estrogen receptor (er) negative breast cancer, er positive breast cancer, triple negative breast cancer (tnbc) and other subtypes of breast cancer.
Antibodies, pharmaceutical compositions and methods
Obi Pharma, Inc.
October 05, 2017 - N°20170283488

Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to stage-specific embryonic antigen 4 (ssea-4) are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as ...
Compounds and methods for kinase modulation, and indications therefor
Obi Pharma, Inc.
October 05, 2017 - N°20170283423

In certain aspects and embodiments, the described compounds or salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof are active on one or more of fms, kit, flt3, trka, trkb and trkc kinase protein. Also described are methods of use thereof to treat diseases and conditions, including diseases and conditions associated with activity of one or more of fms, ...
Breast Cancer Patent Pack
Download 198+ patent application PDFs
Breast Cancer Patent Applications
Download 198+ Breast Cancer-related PDFs
For professional research & prior art discovery
inventor
  • 198+ full patent PDF documents of Breast Cancer-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Poly(adp-ribose) polymerase 1 inhibitors structurally unrelated to nad
Institute For Cancer Research D/b/a The Research Institute Of Fox Chase Cancer Center
October 05, 2017 - N°20170283402

Compounds that are not related to nad, and which target parp1-histone h4 interaction are provided, as well as compositions of these compounds, and methods for specific inhibition of poly(adp-ribose) polymerase 1 (parp-1) using these compounds are provided. These parp-1 inhibitors may be used to treat cancer in which parp-1 activation or biologic activity plays a role, including prostate cancer, ...
C-met antibody drug conjugate
Sorrento Therapeutics, Inc.
October 05, 2017 - N°20170281796

There is disclosed an antibody drug conjugate (adc) having an igg antibody that binds to a c-met target conjugated at both cys sites in the hinge region of an igg antibody. There is further disclosed a method for treating a breast cancer comprising providing an effective amount of a c-met adc.
Markers for breast cancer
Cambridge Enterprise Limited
September 28, 2017 - N°20170275707

Correlations between polymorphisms and breast cancer are provided. Methods of diagnosing, prognosing, and treating breast cancer are provided. Systems and kits for diagnosis, prognosis and treatment of breast cancer are provided. Methods of identifying breast cancer modulators are also described.
Methods and compositions for the treatment of cancer
Children's Medical Center Corporation
September 28, 2017 - N°20170275629

Described herein are methods and compositions relating to the treatment of cancer, e. G., breast cancer, using, e. G., aptamer-sirna chimera molecules.
Histone demethylase inhibitors
Celgene Quanticel Research, Inc.
September 28, 2017 - N°20170275266

Provided herein are substituted pyrazolylpyridine, pyrazolylpyridazine, and pyrazolylpyrimidine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.
Bioconjugation of calcium phosphosilicate nanoparticles for selective targeting of cells in vivo
The Penn State Research Foundation
September 28, 2017 - N°20170274100

Non-aggregating resorbable calcium phosphosilicate nanoparticles (cpnps) are bioconjugated to targeting molecules that are specific for particular cells. The cpnps are stable particles at normal physiological ph. Chemotherapy and imaging agents may be integrally formed with the cpnps so that they are compartmentalized within the cpnps. In this manner, the agents are protected from interaction with the environment at normal physiological ...
A method and composition for treating breast cancer
Stellenbosch University
September 28, 2017 - N°20170274034

The invention disclosed herein relates to the use of an extract of dodonaea viscosa in breast cancer therapy, either alone or in combination with other breast cancer therapies.
Breast Cancer Patent Pack
Download 198+ patent application PDFs
Breast Cancer Patent Applications
Download 198+ Breast Cancer-related PDFs
For professional research & prior art discovery
inventor
  • 198+ full patent PDF documents of Breast Cancer-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Methods for identifying and treating invasive/metastatic cancers
King's College London
September 21, 2017 - N°20170269093

Cancer invasion is a hallmark of metastasis. The mesenchymal mode of cancer cell invasion is mediated by elongated membrane protrusions driven by the assembly of branched f-actin networks. Described herein are compositions and methods for assessing and treating a subject having metastatic cancer or at risk of developing metastatic cancer, e. G., metastatic breast cancer, through the determination of lamellipodin ...
Targeting breast cancer therapy based on stromal subtypes and cd146 composition
The Regents Of The University Of Colorado, A Body Corporate
September 21, 2017 - N°20170269088

Methods for targeted breast cancer therapy in a subject based upon evaluating the stromal subtypes and cd146 composition in the adjacent tissue. Er+ breast cancers contain two caf subtypes defined by cd146 expression. Cd146neg cafs suppress er expression in er+ breast cancer cells, decrease tumor cell sensitivity to estrogen, switch er proliferation dependency toward egfr dependency and decrease tumor ...
Novel read-through fusion polynucleotides and polypeptides and uses thereof
The Regents Of The University Of Colorado, A Body Corporate
September 21, 2017 - N°20170267733

The present disclosure provides for and relates to novel fusion proteins and polypeptides expressed by breast cancer and other cancer cells, and to compositions, materials and methods for detecting, characterizing and treating said breast and other cancers. In one embodiment, the fusion polypeptides are read-through fusion transcripts.
Conjugates of ph low insertion peptide and monomethyl auristatins in the treatment of solid tumors
Lehigh University
September 21, 2017 - N°20170267727

Constructs comprising ph low insertion peptide and variants thereof conjugated to monomethyl auristatins and analogs thereof are described. These constructs are useful, for example, in the treatment of solid tumors, including the treatment of breast cancer and prostate cancer, as well as other cancers such as pancreatic cancer, ovarian cancer, cervical cancer, uterine cancer, lung cancer, skin cancer, kidney cancer, ...
Pharmaceutical composition comprising modified hemoglobin-based therapeutic agent for cancer targeting treatment and diagnostic imaging
Vision Global Holdings Ltd.
September 21, 2017 - N°20170266285

The present invention provides a pharmaceutical composition containing hemoglobin-based therapeutic agent for treating cancer. The hemoglobin moiety can target cancer cells and the therapeutic moiety (i. E. Active agent/therapeutic drug) can kill the cancer cells efficiently. The hemoglobin-based therapeutic agent used in the present invention can be used in the treatment of various cancers such as pancreatic cancer, leukemia, ...
Nonsteroidal and steroidal compounds with potent androgen receptor down-regulation and anti prostate cancer activity
University Of Maryland, Baltimore
September 21, 2017 - N°20170266181

Nonsteroid and steroid compounds that cause down-regulation of the androgen receptor (ar), both full length and splice variant, induce apoptosis and inhibit proliferation of inhibiting proliferation and migration of androgen sensitive cancer cells. The steroid compounds and nonsteroid compounds may be agents for the prevention and/or treatment of cancer, including prostate cancer, castration resistant prostate cancer, bladder cancer, pancreatic ...
Methods for monitoring cd4+ t-helper type 1 response in cancer and immune restoration
The Trustees Of The University Of Pennsylvania
September 14, 2017 - N°20170261508

A method for diagnosing or treating a mammalian subject having, or at risk of developing cancer, comprising: generating a circulating anti-cancer cd4+ th1 response from antigen presenting cells or their precursors and cd4+ t-cells from a sample of said subject's blood which causes secretion of interferon-gamma (“ifn-γ”); and detecting said anti-cancer cd4+ th1 response ...
Post-treatment breast cancer prognosis
The General Hospital Corporation
September 07, 2017 - N°20170253931

The disclosure includes the identification and use of gene expression profiles, or patterns, with clinical relevance to extended treatment and cancer-free survival in a patient. In particular, the disclosure includes the identities of genes that are expressed in correlation with benefit in a switch in endocrine therapy used to treat a patient. The levels of gene expression are disclosed as ...
Loading